Release issued 1st September 2004

Until joining MolecularNature (MNL), Miles was VP-Tumour Immunotherapy at Oxford BioMedica, a UK listed biopharmaceutical company. Within Oxford BioMedica he was instrumental in the invention of the cancer immunotherapeutic 'TroVax' and led it through pre-clinical to phase II clinical trials in late stage cancer patients. He obtained his PhD at the Paterson Institute for Cancer Research, Manchester, where he worked on HIV vaccines. Prior to Oxford Biomedica he developed new recombinant viral vectors for cancer immunotherapy whilst working at the National Institutes for Health in Bethesda, USA.

Miles will join MNL in August 2004 and will take overall responsibility for research and development activities.

Commenting on the appointment Dr Richard Auty, Chairman of MNL, said ' I am pleased to announce the appointment of Miles Carroll to lead the development of MNL's research and development programmes. Miles has an excellent track record and will add to the strength of the MNL management team as we pursue the development of our exciting immunomodulator series. Miles brings both preclinical and clinical development experience'.

About MNL: MNL is a biopharmaceutical company engaged in the discovery and development of drugs that activate and support the body's immune system. MNL was founded in 1999 as a Natural Products company - looking to compounds from plants as the basis for novel discoveries and therapies for major unmet clinical needs. In 2002, MNL made a breakthrough by discovering naturally occurring small molecules that stimulate the immune system (immunomodulators). MNL is developing these as therapeutics to support the human immune system combat chronic diseases. MNL's discoveries are being developed to treat cancers, infectious diseases and other immune system disorders.

For further information contact Hadyn St P Parry , hadyn.parry@molecularnature.com +44 (0) 1628 773583 www.molecularnature.com

(4th July 2003) FIRST SUCCESSES IN NOVEL CANCER DRUG PROGRAMME- PLANTS AND FLOWERS YIELD CANCER REGULATORY DRUGS, NOT JUST AGGRESSIVE CHEMOTHERAPIES

(1st June 2003) MolecularNature Ltd. Announces New Cancer Research Programme

(21st April 2003) Serenex Molecularnature Collaboration

(31st July 2002) Bio-Quant, Inc. Expands its Natural Product Chemical Library Size and Diversity Through Alliance with MolecularNature Ltd.

(31st January 2002) New Echinacea discoveries from MolecularNature Limited